Drugs / Recombinant
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Supemtek Tetra (previously Supemtek) | — | 2020-11-16 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03598439 | Jul 2018 → Mar 2020 | influenza | Marshfield Clinic Research Foundation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03598439 ↗ |
| Modality | Vaccine | “licensed recombinant influenza vaccine” NCT03598439 ↗ |